2012
11 Siggelkow W, Boehm D, Gebhard S, Battista M, Sicking
I, Lebrecht A, Solbach C, Hellwig B, Rahnenführer J, Koelbl H, Gehrmann
M, Marchan R, Cadenas C, Hengstler ,JG, Schmidt M. Expression of aurora
kinase A is associated with metastasis-free,survival in node-negative
breast cancer patients. BMC Cancer. 2012 Nov 27;12:562. doi:
10.1186/1471-2407-12-562.
10 Chen Z, Gerhold-Ay A, Gebhard S,
Boehm D, Solbach C, Lebrecht A, Battista M,Sicking I, Cotarelo C,
Cadenas C, Marchan R, Stewart JD, Gehrmann M, Koelbl H, Hengstler JG,
Schmidt M. Immunoglobulin kappa C predicts overall survival in
node-negative breast cancer. PLoS One. 2012;7(9):e44741.
9 Godoy
P, Cadenas C, Hellwig B, Marchan R, Stewart J, Reif R, Lohr M, Gehrmann
M, Rahnenführer J, Schmidt M, Hengstler JG. Interferon-inducible
guanylate binding protein (GBP2) is associated with better prognosis in
breast cancer and indicates an efficient T cell response. Breast Cancer.
2012 Sep 22. [Epub ahead of print].
8 Schmidt M, Hellwig B,
Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I,
Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L,
Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling
J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett
R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P,
Rahnenführer J, Hengstler JG. A comprehensive analysis of human gene
expression profiles identifies stromal immunoglobulin ? C as a
compatible prognostic marker in human solid tumors. Clin Cancer Res.
2012 May 1;18(9):2695-703.
7 Martin M, Müller K, Cadenas C,
Hermes M, Zink M, Hengstler JG, Käs JA. ERBB2 overexpression triggers
transient high mechanoactivity of breast tumor cells. Cytoskeleton
(Hoboken). 2012 May;69(5):267-77.
2011
6 Schmidt M, Petry IB, Böhm D, Lebrecht A, von Törne C, Gebhard S, Gerhold-Ay A, Cotarelo C, Battista M, Schormann W, Freis E, Selinski S, Ickstadt K, Rahnenführer J, Sebastian M, Schuler M, Koelbl H, Gehrmann M, Hengstler JG. Ep-CAM RNA expression predicts metastasis free survival in three cohorts of untreated node negative breast cancer. Breast Cancer Res Trea. 2011 Feb; 125(3):637-46
2010
5 Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H,
Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC. ERBB2 and TOP2A in
breast cancer: a comprehensive analysis of gene amplification, RNA
levels, and protein expression and their influence on prognosis and
prediction. Clin Cancer Res. 2010 Apr 15;16(8):2391-401. doi:
10.1158/1078-0432.CCR-09-2471
4 Cadenas C, Franckenstein D,
Schmidt M, Gehrmann M, Hermes M, Geppert B, Schormann W, Maccoux LJ,
Schug M, Schumann A, Wilhelm C, Freis E, Ickstadt K, Rahenenfuehrer J,
Baumbach JI, Sickmann A, Hengstler JG. Role of thioredoxin reductase 1
and thioredoxin interacting protein in prognosis of breast cancer.
Breast Cancer Res. 2010 Jun 28;12(3):R44. [Epub ahead of print].
doi:10.1186/bcr2599
3 Hellwig B, Hengstler JG, Schmidt M,
Gehrmann MC, Schormann W, Rahnenführer J. Comparison of scores for
bimodality of gene expression distributions and genome-wide evaluation
of the prognostic relevance of high-scoring genes. BMC Bioinformatics.
2010 May 25;11:276.doi: 10.1186/1471-2105-11-276
2 Petry IB,
Fieber E, Schmidt M, Gehrmann M, Gebhard S, Hermes H, Schormann W,
Selinski S, Freis E, Schwender H, Brulport M, Ickstadt K, Rahnenführer
J, Maccoux L, West J, Kölbl H, Schuler M, Hengstler JG. ERBB2 induces an
antiapoptotic expression pattern of Bcl-2 family members in
node-negative breast cancer. Clin Cancer Res. 2010 Jan
15;16(2):451-60.doi: 10.1158/1078-0432.CCR-09-1617
1 Schmidt M,
Petry IB, Böhm D, Lebrecht A, von Törne C, Gebhard S, Gerhold-Ay a,
Cotarelo C, Battista M, Schormann W, Freis E, Selinski S, Ickstadt K,
Rahnenführer J, Sebastian M, Schuler M, Koelbl H, Gehrmann M, Hengstler
JG. Ep-Cam RNA expression predicts metastasis-free survival in three
cohorts of untreated node-negative breast cancer. Breast Cancer Res
Treat. 2010 Mar 30. [Epub ahead of print]. doi:10.1007/s10549-010-0856-5